Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The DEDICATE trial of TAVR vs SAVR, more on renal denervation, inclisiran, and marketing disguised as science are the topics John Mandrola, MD, discusses in today's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. TAVR vs SAVR
TAVI Comparable With SAVR in Lower-Risk Aortic Stenosis
https://www.medscape.com/viewarticle/tavi-comparable-savr-lower-risk-aortic-stenosis-2024a100074o?form=fpf
- DEDICATE https://www.nejm.org/doi/full/10.1056/NEJMoa2400685
- Partner 3 https://www.nejm.org/doi/full/10.1056/NEJMoa1814052
- Evolut Low Risk https://www.nejm.org/doi/full/10.1056/NEJMoa1816885
- Barili meta-analysis https://doi.org/10.1093/ejcts/ezab516
II. Renal Denervation
Alcohol-Mediated Renal Denervation Promising in Hypertension
https://www.medscape.com/viewarticle/alcohol-mediated-renal-denervation-promising-hypertension-2024a10007eg
- TARGET 1 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069291
III. Inclisiran
Earlier Inclisiran Gives Better Long-Term LDL Reductions
https://www.medscape.com/viewarticle/earlier-inclisiran-gives-better-long-term-ldl-reductions-2024a10007d6
- VICTORIAN INITIATE Trial https://www.jacc.org/doi/10.1016/j.jacc.2024.03.382
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]